Considerations for treatment duration in responders to immune checkpoint inhibitors
JournalJournal for ImmunoTherapy of Cancer
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractImmune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially paid to how much therapy would be needed for a durable response. As the early immunotherapy trials have matured past 10 years, a significant per cent of patients have demonstrated durable responses; it is now time to determine whether patients have been overtreated, and if durable remissions can still be achieved with less therapy, limiting the physical and financial toxicity associated with years of treatment. Well-designed trials are needed to identify optimal duration of therapy, and to define biomarkers to predict who would benefit from shorter courses of immunotherapy. Here, we outline key questions related to health, financial and societal toxicities of over treating with ICI and present four unique clinical trials aimed at exposing criteria for early cessation of ICI. Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI. Copyright 2021 BMJ Publishing Group. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15195
- Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.
- Authors: Robert C, Marabelle A, Herrscher H, Caramella C, Rouby P, Fizazi K, Besse B
- Issue date: 2020 Nov
- An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
- Authors: O'Reilly A, Hughes P, Mann J, Lai Z, Teh JJ, Mclean E, Edmonds K, Lingard K, Chauhan D, Lynch J, Au L, Ludlow A, Pattison N, Wiseman T, Turajlic S, Gore M, Larkin J, Husson O
- Issue date: 2020 Feb
- Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
- Authors: Ouwerkerk W, van den Berg M, van der Niet S, Limpens J, Luiten RM
- Issue date: 2019 Oct
- Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
- Authors: Jessurun CAC, Vos JAM, Limpens J, Luiten RM
- Issue date: 2017
- Rational Approaches to Treatment Duration with Immunotherapy in Metastatic Renal Cell Carcinoma.
- Authors: Singla N, Freifeld Y, Ghandour RA, Hammers HJ
- Issue date: 2020 Jan 15